Conference Detail Page

Neurology: Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study

CME : 0.75
Start Date :  Feb 20 - 2018 End Date :  Feb 20 - 2021

Organized by :   American Academy of Neurology (AAN)

Specialities :   Neurology

Conference Summary

Neurology: Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study is organized by American Academy of Neurology (AAN).

Dates:
Released: 2/20/2018
Expires: 2/20/2021

Accreditation:
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives:
Upon completion of the article by Murata et al, the participant should be able to:
• Briefly discuss the possible antiparkinsonian mechanism of action of zonisamide
• Describe the effect of zonisamide on motor function, cognitive function, caregiver burden, and behavioral and psychological symptoms in this study
• Discuss the rate of adverse effects in patients receiving zonisamide vs placebo in this study

Additional details will be posted as soon as they are available.

Credit Info

  • CME : 0.75
Target Audience

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine

Peers Info
Number of Health Care Professionals Registered: 0 Number
Contact Us

Toll free Number

1(800) 826-2059

Email

support@eMedEvents.com

Chat Assistant

Live Chat